


myrophine, nabumetone, nalbuphine, nalorphine, 1-naphthyl salicylate, naproxen, narceine, nefopam, nicomorphine, nifenazone, niflumic acid, nimesulide, 5'-nitro-2'-propoxyacetanilide, norlevorphanol, normethadone, normorphine, norpipanone, olsalazine, opium, oxaceprol, oxametacine, oxaprozin, oxycodone, oxymorphone, oxyphenbutazone, papaveretum, paramethasone, paranyline, parsalmide, pentazocine, perisoxal, phenacetin, phenadoxone, phenazocine, phenazopyridine hydrochloride, phenocoll, phenoperidine, phenopyrazone, phenomorphan, phenyl acetylsalicylate, phenylbutazone, phenyl salicylate, phenyramidol, piketoprofen, piminodine, pipebuzone, piperylone, pirazolac, piritramide, piroxicam, pirprofen, pranoprofen, prednicarbate, prednisolone, prednisone, prednival, prednylidene, proglumetacin, proheptazine, promedol, propacetamol, properidine, propiram, propoxyphene, propyphenazone, proquazone, protizinic acid, proxazole, ramifenazone, remifentanil, rimazolium metilsulfate, salacetamide, salicin, salicylamide, salicylamide *o*-acetic acid, salicylic acid, salicylsulfuric acid, salsalate, salverine, simetride, sufentanil, sulfasalazine, sulindac, superoxide dismutase, suprofen, suxibuzone, talniflumate, tenidap, tenoxicam, terofenamate, tetrandrine, thiazolinobutazone, tiaprofenic acid, tiaramide, tilidine, tinoridine, tixocortol, tolfenamic acid, tolmetin, tramadol, triamcinolone, triamcinolone acetone, tropesin, viminol, xenbucin, ximoprofen, zaltoprofen and zomepirac.

32. (New) The composition of Claim 25 wherein the anti-inflammatory agent comprises a steroid.
33. (New) The composition of Claim 25 wherein the anti-inflammatory agent comprises a non-steroidal anti-inflammatory drug.
34. (New) The composition of Claim 25 wherein the anti-inflammatory agent comprises a selective COX-2 inhibitor.
35. (New) The composition of Claim 34 wherein the selective COX-2 inhibitor is a compound having the formula



where  $R^5$  is a methyl or amino group,  $R^6$  is hydrogen or a  $C_{1-4}$  alkyl or alkoxy group,  $X'$  is N or  $CR^7$  where  $R^7$  is hydrogen or halogen, and Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is optionally substituted at one or more positions with oxo, halo, methyl or halomethyl groups.

36. (New) The composition of Claim 34 wherein the selective COX-2 inhibitor is selected from the group consisting of deracoxib, parecoxib, celecoxib, valdecoxib, rofecoxib, etoricoxib, lumiracoxib, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one, (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3-(2H)-pyridazinone, 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, 4-[5-(phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, salts and prodrugs thereof.
37. (New) The composition of Claim 34 wherein said selective COX-2 inhibitor is present at a concentration of 0.01 to 1000 mg/ml.
38. (New) The composition of Claim 34 wherein said selective COX-2 inhibitor is present at a concentration of 0.1 to 750 mg/ml.
39. (New) The composition of Claim 34 wherein said selective COX-2 inhibitor is present at a concentration of 5 to 250 mg/ml.
40. (New) The composition of any of Claims 25-39 wherein the amphipathic oil is a polyglycolized glyceride prepared by an alcoholysis reaction of natural triglycerides

with polyethylene glycols.

41. (New) The composition of Claim 40 wherein the polyglycolized glyceride comprises a main fatty acid component of oleic acid or linoleic acid.
42. (New) The composition of Claim 40 wherein the polyglycolized glyceride comprises a main fatty acid component of oleic acid.
43. (New) The composition of Claim 40 wherein the polyglycolized glyceride is pegicol 5-oleate.
44. (New) The composition of Claim 40 wherein the amphipathic oil constitutes 0.01% to 99% weight/volume of the composition.
45. (New) The composition of Claim 40 wherein the amphipathic oil constitutes 1% to 80% weight/volume of the composition.
46. (New) The composition of Claim 25 wherein the amphipathic oil constitutes 3% to 25% weight/volume of the composition.
47. (New) The composition of Claim 25 wherein the microcrystalline wax constitutes 0.001% to 50% weight/volume of the composition.
48. (New) The composition of Claim 25 wherein the microcrystalline wax constitutes 0.1% to 40% weight/volume of the composition.
49. (New) The composition of Claim 25 wherein the microcrystalline wax constitutes 1% to 15% weight/volume of the composition.
50. (New) The composition of any of Claims 25-39 wherein the non-aqueous carrier is selected from the group consisting of vegetable oils, mineral oils, medium to long chain fatty acids and alkyl esters thereof, propylene glycol di-esters of medium to long chain fatty acids, mono-, di-, and triglyceryl esters of fatty acids, polyethylene glycols, and combinations thereof.
51. (New) The composition of Claim 50 wherein the non-aqueous carrier is a vegetable oil selected from the group consisting of cottonseed oil, corn oil, sesame oil, soybean oil, olive oil, coconut oil, fractionated coconut oils, peanut oil, sunflower

oil, safflower oil, almond oil, avocado oil, palm oil, palm kernel oil, babassu oil, beechnut oil, linseed oil, rape oil and combinations thereof.

52. (New) The composition of Claim 50 wherein the non-aqueous carrier is cottonseed oil.
53. (New) The composition of Claim 50 wherein the non-aqueous carrier comprises capric acid in an amount of 20% to 45% and caprylic acid in an amount of 45% to 80% by weight of the non-aqueous carrier.
54. (New) The composition of Claim 50 wherein the non-aqueous carrier constitutes 0.5% to 99% weight/volume of the composition.
55. (New) The composition of Claim 50 wherein the non-aqueous carrier constitutes 10% to 95% weight/volume of the composition.
56. (New) The composition of Claim 50 wherein the non-aqueous carrier constitutes 40% to 90% weight/volume of the composition.
57. (New) The composition of any of Claims 25-39 that further comprises at least one excipient selected from the group consisting of antioxidants, preservatives, stabilizers, wetting agents, lubricants, emulsifiers, salts for influencing osmotic pressure, coloring agents, alcohols and buffering agents.
58. (New) The composition of Claim 25 wherein the polyglycolized glyceride is pegicol 5-oleate; the non-aqueous carrier is cottonseed oil; and the anti-inflammatory agent comprises a selective COX-2 inhibitor.
59. (New) An article of manufacture comprising a container or delivery device having an oxygen permeable wall, and having contained therein the composition of Claim 25.
60. (New) The article of Claim 59 wherein said wall is constructed of an oxygen permeable material comprising polyethylene.
61. (New) The article of Claim 59 wherein the composition exhibits extended chemical and/or physical stability.